Fermenta Biotech
Healthcare
FERMENTA NSE
₹439.80 +11.85 (+2.77%)
- P/E
- 21.69
Close 4 Nov 2026 ₹439.80 +163.50 +59.2% 1Y
Start ₹276.30
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 20.60%
- Debt to Equity
- 0.28
- EPS (TTM)
- ₹20.28
- Book Value
- ₹138.15
- Market Cap
- —
- P/E (TTM)
- 21.69
- P/B
- 3.18
- ROE
- 16.40%
- Dividend Yield
- 0.88%
- EBITDA
- ₹122 Cr
- 52W High
- ₹582.65
- 52W Low
- ₹248.85
- Day Range
- ₹426.60 – ₹450.55
- Volume
- 57,584
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Fermenta Biotech (this company) | ₹439.80 | 21.69 | ₹1,260 Cr | 3.18 | 0.88% | 16.40% | 20.60% | ₹511 Cr | ₹58 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.70% | 16.45% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
56 Good
Data confidence 100/100
insider_selling
Category scores
- Quality
- 60
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 80
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 8
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 52
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 69
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
4- Promoter holding has decreased over last quarter: -3.96%
- The company has delivered a poor sales growth of 6.85% over past five years.
- Company has a low return on equity of 12.6% over last 3 years.
- Working capital days have increased from 48.7 days to 96.2 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 9 | 5 | 5 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 7 | 0 | 3 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Bearish
Bearish
9
Neutral
5
Bullish
5
Moving Averages
Strong Bearish
Bearish
7
Neutral
0
Bullish
3
Key readings
- RSI (14)
- 38.77
- Neutral
- MACD (12,26,9)
- −19.67
- Bearish
- SMA (50)
- 486.05
- Bearish
- SMA (200)
- 388.02
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +12.93% |
|---|---|
| 5Y | +6.82% |
| 3Y | +14.43% |
| 1Y | +11.75% |
| TTM | −3.15% |
Net profit
| 10Y | +42.69% |
|---|---|
| 5Y | +10.24% |
| 3Y | Turned to profit |
| 1Y | −7.89% |
| TTM | −44.02% |
Operating cash flow
| 10Y | +36.98% |
|---|---|
| 5Y | +8.10% |
| 3Y | −7.10% |
| 1Y | +126.83% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +5.76 pp |
|---|---|
| 5Y | −2.76 pp |
| 3Y | +14.15 pp |
| 1Y | −5.26 pp |
| TTM | −8.46 pp |
Revenue by year
| Mar 2017 | ₹164 Cr |
|---|---|
| Mar 2018 | ₹302 Cr |
| Mar 2019 | ₹403 Cr |
| Mar 2020 | ₹292 Cr |
| Mar 2021 | ₹376 Cr |
| Mar 2022 | ₹397 Cr |
| Mar 2023 | ₹349 Cr |
| Mar 2024 | ₹335 Cr |
| Mar 2025 | ₹468 Cr |
| Mar 2026 | ₹523 Cr |
Net profit by year
| Mar 2017 | −₹9.00 Cr |
|---|---|
| Mar 2018 | ₹46.00 Cr |
| Mar 2019 | ₹117 Cr |
| Mar 2020 | ₹60.00 Cr |
| Mar 2021 | ₹43.00 Cr |
| Mar 2022 | ₹15.00 Cr |
| Mar 2023 | −₹53.00 Cr |
| Mar 2024 | −₹24.00 Cr |
| Mar 2025 | ₹76.00 Cr |
| Mar 2026 | ₹70.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82.45 | 56.91 | 98.97 | 97.34 | 78.13 | 95.03 | 156 | 140 | 136 | 130 | 137 | 122 | 122 |
| Expenses | 71.52 | 70.82 | 73.84 | 91.96 | 77.33 | 76.25 | 103 | 103 | 108 | 104 | 112 | 102 | 104 |
| Operating Profit | 10.93 | −13.91 | 25.13 | 5.38 | 0.8 | 18.78 | 53.27 | 36.95 | 28.24 | 26.64 | 24.96 | 20 | 18.06 |
| OPM % | 13.26% | −24.44% | 25.39% | 5.53% | 1.02% | 19.76% | 34.04% | 26.42% | 20.73% | 20.46% | 18.17% | 16.45% | 14.83% |
| Other Income | 2.01 | −5.53 | 2.52 | 5.38 | 2.82 | 2.88 | 2.23 | 3.89 | 8.77 | 5.43 | 0.92 | 14.14 | 4.37 |
| Interest | 4.78 | 3.69 | 5.19 | 3.39 | 3.43 | 3.69 | 4.08 | 2.99 | 3.11 | 2.58 | 3.03 | 2.82 | 2.54 |
| Depreciation | 5.95 | 5.93 | 6.38 | 6.46 | 6.12 | 6.15 | 6.08 | 5.86 | 5.81 | 5.41 | 5.37 | 5.11 | 5.2 |
| PBT | 2.21 | −29.06 | 16.08 | 0.91 | −5.93 | 11.82 | 45.34 | 31.99 | 28.09 | 24.08 | 17.48 | 26.21 | 14.69 |
| Tax % | 0% | 0% | 37.81% | 884.62% | 0% | 5.92% | 16.43% | −4.19% | 23.07% | 25.17% | 31.24% | 29.03% | 35.13% |
| Net Profit | 2.21 | −29.07 | 9.99 | −7.14 | −5.93 | 11.12 | 37.89 | 33.32 | 21.6 | 18.03 | 12.02 | 18.6 | 9.53 |
| EPS (₹) | 0.62 | −9.7 | 3.35 | −2.36 | −1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.14 | 4.31 | 6.52 | 3.31 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 523 | 511 |
| Expenses | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 422 | 421 |
| Operating Profit | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 101 | 90 |
| OPM % | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 19% | 18% |
| Other Income | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | −20 | 4 | 7 | 29 | 25 |
| Interest | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 | 11 |
| Depreciation | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 22 | 21 |
| PBT | 3 | 7 | −6 | 76 | 129 | 43 | 52 | 27 | −51 | −10 | 83 | 96 | 82 |
| Tax % | 67% | 61% | 49% | 28% | 8% | −37% | 18% | 44% | 4% | 143% | 8% | 27% | — |
| Net Profit | 1 | 2 | −9 | 46 | 117 | 60 | 43 | 15 | −53 | −24 | 76 | 70 | 58 |
| EPS (₹) | 0.17 | −0.41 | −4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | −17.36 | −7.84 | 26.12 | 24.39 | 20.28 |
| Div. Payout % | 249% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 2% | 1% | 24% | 16% | 23% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 9% | 15% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 14 |
| Reserves | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 392 |
| Borrowings | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 113 |
| Other Liabilities | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 128 |
| Total Liabilities | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
| Fixed Assets | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 220 |
| CWIP | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 |
| Investments | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 414 |
| Total Assets | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 | 93 |
| Investing | −18 | −13 | 7 | −101 | −97 | −44 | −41 | −26 | −55 | −16 | 0 | −43 |
| Financing | 1 | 10 | −12 | 89 | 12 | −47 | −1 | −22 | −41 | −91 | −51 | −42 |
| Net Cash Flow | −2 | 1 | −4 | 47 | 6 | −57 | 21 | −4 | 19 | −1 | −10 | 8 |
| Free Cash Flow | −20 | −25 | −17 | 42 | 55 | −34 | 7 | 6 | 76 | 86 | 38 | 63 |
| CFO/EBITDA | 119 | 35 | 35 | 83 | 79 | 73 | 92 | 85 | 610 | 370 | 38 | 108 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 | 78 |
| Inventory Days | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 285 | 290 |
| Days Payable | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 178 | 147 |
| Cash Conversion Cycle | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 181 | 221 |
| Working Capital Days | −61 | −49 | 33 | 54 | 43 | 70 | 54 | 67 | −18 | 9 | 40 | 96 |
| ROCE % | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | 0% | 3% | 23% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Fermenta Biotech insights
65 extracted metrics across FY15–FY27.
Documents
- 20 Aug 2026
- 1 Oct 2025
- 25 Feb 2025
- 4 Apr 2024
- 17 Nov 2023
- General announcements 12 Oct 2026
- General announcements 9 Oct 2026
- General announcements 8 Oct 2026
Frequently Asked Questions about Fermenta Biotech
What does Fermenta Biotech Ltd do?
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products
Where is Fermenta Biotech Ltd (FERMENTA) listed?
Fermenta Biotech Ltd trades as FERMENTA on the NSE and under code 506414 on the BSE.
Which sector does Fermenta Biotech Ltd belong to?
Fermenta Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Fermenta Biotech Ltd?
Fermenta Biotech Ltd trades at a PE ratio of 21.69 as of 4 Nov 2026, on earnings per share of ₹20.28, against a book value of ₹138.15 per share.
What is the 52-week high and low of Fermenta Biotech Ltd?
Over the last 52 weeks Fermenta Biotech Ltd has traded between ₹248.85 and ₹582.65 as of 4 Nov 2026.
Does Fermenta Biotech Ltd pay dividends?
Fermenta Biotech Ltd has a dividend yield of 0.88%.
What is the Return on Equity (ROE) of Fermenta Biotech Ltd?
Fermenta Biotech Ltd reported a return on equity of 16.40%. Its debt-to-equity ratio is 0.28.
Company Information
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506414.md for Fermenta Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.